Oncotelic Therapeutics (OTCQB: OTLC) announced the launch of its artificial intelligence-powered good manufacturing practices (GMP) manufacturing services platform at the 2026 BIO International Convention in San Diego. The platform combines the company’s proprietary PDAOAI technology with advanced robotics provided through its collaboration with TechForce Robotics, aiming to support pharmaceutical, biotechnology and advanced therapeutics companies seeking to modernize manufacturing operations through AI-driven workflows, digital quality systems and intelligent automation.
According to Oncotelic, the platform is designed to handle electronic batch records, manufacturing documentation, GMP workflow digitization, quality and compliance functions and process monitoring. This initiative represents a significant step in integrating artificial intelligence into the highly regulated pharmaceutical manufacturing sector, potentially reducing errors, increasing efficiency and accelerating time-to-market for new therapies.
In addition to the platform launch, Oncotelic will showcase progress with its Deciparticle nanomedicine platform, including SAPU003, its clinical-stage intravenous everolimus program currently being evaluated in a Phase 1b study. The company’s presence at BIO 2026 highlights its dual focus on advanced manufacturing solutions and novel therapeutic development.
Oncotelic’s CEO, Dr. Vuong Trieu, has filed over 500 patent applications and holds 75 issued U.S. patents, underscoring the company’s innovative foundation. Beyond internal programs, Oncotelic licenses and co-develops select drug candidates through joint ventures. Currently, the company owns 45% of GMP Bio, a joint venture advancing its own pipeline of drug candidates that complement Oncotelic’s strategic position in oncology and rare disease therapeutics.
The PDAOAI platform also supports Oncotelic’s relationship with SAPU Bio, an OEB-5 sterile injectable cGMP manufacturing facility, and ongoing joint development work with TechForce Robotics. TechForce Robotics, the operating brand of Nightfood Holdings, Inc., designs and deploys purpose-built robotics and automation solutions for service, hospitality and pharmaceutical manufacturing applications. For more information about TechForce, visit www.techforcerobotics.com.
The launch of this AI-powered GMP platform is important because it addresses a critical need in the pharmaceutical industry for more efficient, compliant and scalable manufacturing processes. By leveraging AI and robotics, Oncotelic aims to help biotech and pharma companies reduce manual errors, streamline regulatory compliance and potentially lower costs. This could accelerate the development and delivery of life-saving therapies to patients. For more details on the announcement, visit https://ibn.fm/upnBW. For the latest news on Oncotelic, see https://ibn.fm/OTLC.
